Jazz Pharmaceuticals announced it will appoint Renee Gala as CEO, succeeding the retiring Bruce Cozadd. Gala currently serves as Chief Operating Officer. The leadership change occurs during active clinical development phases for Jazz and partner companies Ultragenyx and Mereo, with recent trial updates impacting investor outlook. The transition aims to build on Jazz’s strategic growth initiatives and pipeline maturation in specialty pharmaceuticals.